Inositol Polyphosphate-4-Phosphatase Type II promotes gemcitabine resistance in pancreatic ductal adenocarcinoma cells via lysosomal exocytosis
Melo, C. M. P.; Newell, C.; Saffi, G. T.; Ng, N.; Yu, C.; Wang, C. A.; To, L.; Chow, J. T.-S.; Salmena, L.
Show abstract
Chemotherapy resistance is a major challenge in pancreatic ductal adenocarcinoma (PDAC). While high Inositol Polyphosphate-4-Phosphatase Type II (INPP4B) expression correlates with poor outcomes, its function in chemotherapy response is unclear. We show that INPP4B promotes gemcitabine resistance by enhancing lysosomal exocytosis. Across PDAC models, high INPP4B linked to reduced gemcitabine sensitivity, while knockdown restored it. INPP4B also conferred cross-resistance to agents including irinotecan, oxaliplatin, paclitaxel, and daunorubicin. Mechanistically, INPP4B increased cell-surface LAMP1, enhanced extracellular gemcitabine release, and mitigated DNA damage. Pharmacological targeting of lysosomes with chloroquine (CQ), Bafilomycin A (BafA), or specific PIKfyve or TRPML1 inhibitors blocked exocytosis and reversed resistance in vitro. Moreover, chloroquine co-treatment restored gemcitabine sensitivity in INPP4B-overexpressing xenografts. These results establish INPP4B-driven lysosomal exocytosis as a key mechanism of gemcitabine resistance, highlighting a therapeutic target for PDAC resensitization.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma 93%
- TET2 drives 5hmc marking of GATA6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes 93%
- Loss of Rnf43 accelerates Kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma 92%
Similar papers in this journal
- Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells 92%
- Distinct Mechanisms of Innate and Adaptive Immune Regulation Underlie Poor Oncologic Outcomes Associated with KRAS-TP53 Co-Alteration in Pancreatic Cancer 92%
- Colon Cancer Cells Evade Drug Action by Enhancing Drug Metabolism 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.